Aurobindo's Eugia Steriles Gets 5 USFDA Observations After Pre-Approval Inspection
Hyderabad: Aurobindo Pharma Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) at Eugia Steriles Private Limited, a stepdown subsidiary of the company, with five observations.
According to the company's regulatory filing, the inspection was conducted at Eugia Steriles Private Limited, located at Parawada Mandal in Andhra Pradesh's Anakapalli district. The facility is a wholly owned subsidiary of Eugia Pharma Specialities Limited and a 100% stepdown subsidiary of Aurobindo Pharma Limited.
The US FDA inspection commenced on June 10, 2026, and concluded on June 19, 2026. The inspection was carried out as part of the agency's Pre-Approval Inspection process, which evaluates manufacturing facilities seeking approval for pharmaceutical products intended for the US market.
Aurobindo Pharma stated that the inspection concluded with five observations. The company further indicated that it would respond to the observations within the stipulated timeline prescribed by the regulatory authority.
In its filing, the company reiterated its commitment to maintaining high manufacturing and quality standards across its global operations and stated that it would continue to keep stock exchanges informed of any material developments related to the inspection.
The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. Details provided in the annexure to the filing identified the US FDA as the regulatory authority that conducted the inspection and noted that the communication was received on June 19, 2026.
According to the regulatory filing submitted by Aurobindo Pharma Limited, the observations issued following the inspection do not have any impact on the company's financial position or operational activities. The company stated that there is no quantifiable financial or operational impact arising from the inspection outcome.
